X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (17) 17
humans (16) 16
oncology (13) 13
aged (11) 11
female (11) 11
male (11) 11
middle aged (11) 11
melanoma (8) 8
immunology (7) 7
immunotherapy (7) 7
adult (6) 6
aged, 80 and over (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
article (6) 6
cancer (6) 6
animals (5) 5
cells (5) 5
metastatic melanoma (5) 5
mice (5) 5
t cells (5) 5
treatment outcome (5) 5
braf (4) 4
cell line, tumor (4) 4
disease-free survival (4) 4
medicine & public health (4) 4
melanoma - pathology (4) 4
neoplasm metastasis (4) 4
survival (4) 4
targeted therapy (4) 4
therapy (4) 4
abridged index medicus (3) 3
antineoplastic agents (3) 3
antineoplastic agents - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
bortezomib (3) 3
cancer research (3) 3
cd8-positive t-lymphocytes - immunology (3) 3
clinical trials (3) 3
combination (3) 3
disease progression (3) 3
expression (3) 3
hematology (3) 3
ipilimumab (3) 3
lymphocytes, tumor-infiltrating - immunology (3) 3
melanoma - metabolism (3) 3
mice, inbred c57bl (3) 3
pd-1 (3) 3
progression-free survival (3) 3
rituximab (3) 3
vemurafenib (3) 3
adolescent (2) 2
antibodies, monoclonal, murine-derived - adverse effects (2) 2
antigens (2) 2
antimitotic agents (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
b7-h1 (2) 2
binding (2) 2
biology (2) 2
boronic acids - adverse effects (2) 2
carcinoma, renal cell - therapy (2) 2
cd8-positive t-lymphocytes - cytology (2) 2
cell proliferation (2) 2
cell proliferation - drug effects (2) 2
chemotherapy (2) 2
combined modality therapy (2) 2
cyclophosphamide (2) 2
dosage and administration (2) 2
everolimus (2) 2
flow cytometry (2) 2
gene expression regulation, neoplastic (2) 2
genetic engineering (2) 2
homeostasis - immunology (2) 2
immunohistochemistry (2) 2
interferon-alpha (2) 2
kaplan-meier estimate (2) 2
kidney neoplasms - therapy (2) 2
lymphocyte activation - immunology (2) 2
lymphoma, mantle-cell - drug therapy (2) 2
mantle cell lymphoma (2) 2
medicine, research & experimental (2) 2
mek (2) 2
melanoma - genetics (2) 2
memory (2) 2
mice, knockout (2) 2
multicenter (2) 2
mutation (2) 2
neoplasm staging (2) 2
non-hodgkin lymphoma (2) 2
non-hodgkin's lymphomas (2) 2
non‐hodgkin lymphoma (2) 2
original research (2) 2
pd-l1 (2) 2
pd‐1 (2) 2
pd‐l1 (2) 2
prognosis (2) 2
programmed cell death 1 receptor - metabolism (2) 2
proteasome inhibitor bortezomib (2) 2
pyrazines - adverse effects (2) 2
radiotherapy (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Immunology and Immunotherapy, ISSN 0340-7004, 2015, Volume 64, Issue 10, pp. 1241 - 1250
Targeted therapy with sunitinib, pazopanib or everolimus has improved treatment outcome for patients with metastatic renal cell carcinoma patients (RCC).... 
Sunitinib | Immunology | Medicine & Public Health | Tumor-infiltrating lymphocytes | Renal cell carcinoma | Myeloid-derived suppressor cells | Oncology | Cancer Research | Adoptive cell therapy | SURVIVAL | IMMUNOLOGY | COMBINATION | CANCER | INTERFERON-ALPHA | MELANOMA | THERAPY | ONCOLOGY | IMMUNE SUPPRESSION | IMMUNOTHERAPY | T-CELLS | MODULATION | Humans | Middle Aged | Kidney Neoplasms - immunology | Male | Molecular Targeted Therapy | Carcinoma, Renal Cell - immunology | Indoles - administration & dosage | T-Lymphocytes - transplantation | Neoplasm Metastasis | Interleukin-2 - administration & dosage | Myeloid Cells - immunology | Pyrroles - administration & dosage | Immunotherapy | Pyrroles - adverse effects | Adult | Female | Myeloid Cells - drug effects | Everolimus | Kidney Neoplasms - therapy | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Pyrimidines - administration & dosage | Programmed Cell Death 1 Receptor - metabolism | Treatment Outcome | Combined Modality Therapy | Lymphocytes, Tumor-Infiltrating - drug effects | Sirolimus - administration & dosage | Indoles - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - adverse effects | Carcinoma, Renal Cell - therapy | Cell Line, Tumor | Sulfonamides - adverse effects | T-Lymphocytes - immunology | Aged | Cell Proliferation - drug effects | Sulfonamides - administration & dosage | Lymphocytes, Tumor-Infiltrating - immunology | Antimitotic agents | Carcinoma, Renal cell | T cells | Antineoplastic agents
Journal Article
Cancer Immunology and Immunotherapy, ISSN 0340-7004, 06/2016, Volume 65, Issue 6, pp. 753 - 63
T cell checkpoint blockade with antibodies targeting programmed cell death (ligand)-1 (PD-1/PD-L1) and/or cytotoxic T lymphocyte-antigen 4 (CTLA-4) has... 
Immunomodulation | Humans | Melanoma | Antineoplastic Agents | Mice, Transgenic | Combined Modality Therapy | Antibodies, Monoclonal | Journal Article | Animals | Codon | Lymphocytes, Tumor-Infiltrating | Lymphocyte Subsets | Research Support, Non-U.S. Gov't | Biomarkers | Programmed Cell Death 1 Receptor | Mice | Mutation | Antigens, CD137 | Proto-Oncogene Proteins B-raf | Disease Models, Animal | Immunology | Medicine & Public Health | Oncology | Cancer Research | CD137 | Radiotherapy | BRAFV600 | PD-1 | Stereotactic | CELLS | INDUCED APOPTOSIS | TUMOR | RECOMBINANT INTERLEUKIN-2 | IMMUNOLOGY | CANCER | RADIATION-THERAPY | UNTREATED MELANOMA | METASTATIC MELANOMA | ONCOLOGY | NIVOLUMAB | IPILIMUMAB | Immunomodulation - drug effects | Immunomodulation - radiation effects | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Lymphocyte Subsets - immunology | Lymphocyte Subsets - metabolism | Melanoma - genetics | Lymphocytes, Tumor-Infiltrating - metabolism | Antineoplastic Agents - pharmacology | Antibodies, Monoclonal - pharmacology | Melanoma - radiotherapy | Programmed Cell Death 1 Receptor - metabolism | Tumor Necrosis Factor Receptor Superfamily, Member 9 - metabolism | Melanoma - pathology | Proto-Oncogene Proteins B-raf - genetics | Tumor Necrosis Factor Receptor Superfamily, Member 9 - antagonists & inhibitors | Melanoma - drug therapy | Lymphocytes, Tumor-Infiltrating - immunology | Viral antibodies | Antigens | Interleukins | Immunotherapy | Genetically modified organisms | Antibodies | Genetic engineering | T cells | Original
Journal Article
Investigational New Drugs, ISSN 0167-6997, 2/2014, Volume 32, Issue 1, pp. 195 - 199
Journal Article
OncoImmunology, ISSN 2162-4011, 08/2012, Volume 1, Issue 5, pp. 609 - 617
The development of targeted therapies and immunotherapies has markedly advanced the treatment of metastasized melanoma. While treatment with selective BRAF... 
targeted therapy | T cell | immunotherapy | ipilimumab | vemurafenib | melanoma | BRAF | CTLA-4 | PLX4720 | Binding | Proteins | Landes | Calcium | Bioscience | Biology | Cell | Cycle | Cancer | Organogenesis | Vemurafenib | Targeted therapy | Immunotherapy | Ipilimumab | Melanoma | ANTIGEN-4 BLOCKADE | REGULATORY T | IMMUNOLOGY | COMBINATION | CHEMOTHERAPY | METASTATIC MELANOMA | T-CELL INFILTRATION | THERAPY | ONCOLOGY | CUTANEOUS MELANOMA | RADIOTHERAPY | Research Paper
Journal Article
Journal Article
OncoImmunology, ISSN 2162-402X, 12/2016, Volume 5, Issue 12, p. e1238557
Immunotherapy of advanced melanoma with CTLA-4 or PD-1/PD-L1 checkpoint blockade induces in a proportion of patients long durable responses. In contrast,... 
checkpoint blockade | targeted therapy | MEK | Anti-PD-1 | PI3K | immunotherapy | mTOR | melanoma | BRAF | MAPK | BRAF-MUTATED MELANOMA | HUMAN-LYMPHOCYTES | IMPROVED SURVIVAL | T-CELL | IMMUNOLOGY | ANTITUMOR-ACTIVITY | UNTREATED MELANOMA | METASTATIC MELANOMA | MTOR INHIBITION | MEK INHIBITION | ONCOLOGY
Journal Article
Journal Article
Journal Article
Journal Article
American Journal of Hematology, ISSN 0361-8609, 03/2006, Volume 81, Issue 3, pp. 199 - 201
Journal Article
American Journal of Pathology, The, ISSN 0002-9440, 2012, Volume 181, Issue 3, pp. 785 - 794
The MAP kinase and PI3 kinase pathways have been identified as the most common pathways that mediate oncogenic transformation in melanoma, and the majority of... 
Pathology
Journal Article
Journal Article
15.